GlassScriptPhysician profile
Susan Burke
NPI 1528069606
$1,403.79
in general payments reported to CMS, 2019-2025
21 companies · $209 in 2025
The $209 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $140 · 2021: $237 · 2022: $253 · 2023: $164 · 2024: $188 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $162.11 | 2020-2025 | Vaxelis, Gardasil 9, Rotateq |
| Cranial Technologies, INC | $152.54 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $144.36 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.37 | 2019-2024 | Elaprase |
| Pfizer INC. | $120.40 | 2023-2024 | |
| Sobi, INC | $109.20 | 2019-2023 | |
| Tris Pharma INC | $87.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $80.32 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $62.51 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $58.48 | 2021-2022 | |
| Corium, LLC | $43.55 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $37.38 | 2019-2020 | |
| Photonicare INC | $35.51 | 2025 | Otosight Middle Ear Scope |
| Philips North America LLC | $33.87 | 2019 | |
| Seqirus USA INC | $30.58 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $27.39 | 2023 | Auvi-Q |
| Lnhc, INC | $22.25 | 2025 | Zelsuvmi |
| Shire North American Group INC | $16.26 | 2019 | |
| Genentech USA, INC. | $15.76 | 2020 | |
| Biomarin Pharmaceutical INC. | $14.49 | 2024 | Voxzogo 1.2mg |
| Abbvie INC. | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.